| Description |
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity[1].
|
| Related Catalog |
|
| In Vitro |
Onartuzumab acts specifically by blocking HGF α-chain (but not β-chain) binding to MET[1]. Onartuzumab blocks HGF binding to human c-Met with an inhibitory concentration (IC)50 of 1.8 nM and inhibits the subsequent induction of c-Met auto-phosphorylation and cell proliferation in many cancer cell lines[2].
|
| In Vivo |
Onartuzumab (30 mg/kg, IP, twice a week for 2 mouth) suppresses tumor growth[3]. Animal Model: Human HGF-transgenic SCID mice implanted with BxPC3 tumor cells, nude (nu/nu) mice implanted with KP4 human pancreatic xenograft tumor cells[3] Dosage: 30 mg/kg Administration: IP, twice a week for 2 mouth Result: Suppressed tumor growth, but did not affect the mean in vivo human HGF levels. Animal Model: U-87 MG tumor-bearing mice[3] Dosage: 30 mg/kg Administration: IP, once Result: Resulted in profound TGI (tumor growth inhibition) with 4/10 mice demonstrating a partial response (>50% reduction in tumor size) and 6/10 mice demonstrating a complete response (100% tumor regression).
|
